Navigation Links
Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
Date:9/17/2009

st; the impact of weight loss on health; the treatment of patients with new mechanistic and better tolerated approaches; lorcaserin's patent coverage; and Arena's focus, strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Arena's lorcaserin program and other of its research and development programs; results of clinical trials or preclinical studies may not be predictive of future results and top-line results are preliminary; clinical trials and studies may not proceed at the time or in the manner Arena expects or at all; Arena's ability to partner or commercialize lorcaserin or other of its compounds or programs; the timing and ability of Arena to receive regulatory approval for its drug candidates; Arena's ability to obtain additional funds; Arena's ability to obtain and defend its patents; and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

    Contact: Arena Pharmaceuticals, Inc.     Media Contact: Russo Partners

    Jack Lief
    President and CEO                        David Schull, President
                                             '/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... LONDRES, August 30, 2015 ... de l cuidado al paciente ... trayecto   Royal Philips  (NYSE: ... de IntelliSpace Cardiovascular , un sistema web de ... para acceder, analizar y compartir imágenes cardiovasculares e información ...
(Date:8/28/2015)... Fla. , Aug. 28, 2015  With the ... reaching deadlier heights, Jacksonville -based ... Philip Hemphill is helping to explain why fentanyl ... is approximately 40 to 50 times more potent than ... recreational users as heroin, the risk of death skyrockets. ...
(Date:8/28/2015)... 28, 2015  CytomX Therapeutics, Inc., a biopharmaceutical company ... announced the filing of a registration statement on Form ... relating to a proposed initial public offering of its ... and the price range for the offering have not ... stock under the symbol "CTMX" on the NASDAQ Global ...
Breaking Medicine Technology:Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2CytomX Files Registration Statement for Proposed Initial Public Offering 2
... Pevion Biotech AG today announced ... therapeutic Candida vaccine PEV7, demonstrating the generation of specific ... Furthermore, the results again confirm the capability of Pevion,s ... long-lasting immunity in humans against otherwise weak antigens ...
... Mass. and MIAMI, Jan. 16, 2012 Boston Scientific ... endpoint data from its ORION trial, demonstrating excellent outcomes ... patients with iliac artery disease, a form of peripheral ... insufficient blood flow.  Results were presented today by Daniel ...
Cached Medicine Technology:Pevion's Therapeutic Candida Vaccine Generates Functional B Cell Memory in all Vaccinees 2Pevion's Therapeutic Candida Vaccine Generates Functional B Cell Memory in all Vaccinees 3Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 2Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 3Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 4Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 5
(Date:8/31/2015)... ... August 31, 2015 , ... Thermi, a ... is proud to announce South Korea’s Ministry of Food and Drug Safety ... most sought-after radio frequency thermotherapy technology available in United States, South Korea, Thailand, ...
(Date:8/30/2015)... , ... August 30, 2015 , ... ProTrailer Party is ... X. ProTrailer Party contains 30 styled and detailed presets, allowing FCPX users to ... each title, these titles will help film makers save time while adding professional titles ...
(Date:8/30/2015)... ... August 31, 2015 , ... Intellitec Solutions, ... Convention & Expo October 5th & 6th in San Antonio, TX. Dedicated to ... brings industry professionals from all over the country come to share the latest ...
(Date:8/30/2015)... ... August 30, 2015 , ... Lizzie’s Lice Pickers , a company that ... company is currently offering lice head checks for just $10, which is a significant ... 10% discount on their lice treatment products. “With kids returning to school, it is ...
(Date:8/30/2015)... Fl (PRWEB) , ... August 30, 2015 , ... ... Executive Vice President Jeff Fernandez will lead the expansion of global cosmeceutical and ... and skin care experience having spent the last 25 years working in operations, ...
Breaking Medicine News(10 mins):Health News:Thermi Heats Up South Korea Announcing Global Expansion with NewRegulatory Approvals for ThermiRF™ 2Health News:FCPX Effects Developer Releases ProTrailer Party for Final Cut Pro X 2Health News:Intellitec Solutions to feature Microsoft Dynamics GP at AHCA/NCAL 66th Annual Convention & Expo 2Health News:Lizzie’s Lice Pickers Announces Back to School Head Check Special and Discounted Lice Treatment Products 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2
... in the nation,s healthcare system looming and overall physician frustration ... at the Wynn Las Vegas this November has a very ... careers. The Medical Fusion conference ( http://www.MedFusionConf.org ... tapping into the growing frustration of physicians practicing clinical medicine ...
... Systems, Inc. Will Add RALS(R)-Plus Module to Company,s Hemoglobin ... June 22 HemoCue Inc., the U.S. ... DGX ), today announced that it has ... for the development of a RALS(R)-Plus module for the ...
... greater emphasis on preventive care to universal electronic records ... continue to debate the details of what many hope ... nation,s health-care system. While no fully formed proposals have ... , Evidence-based guidelines. , During a speech ...
... Kit is First to Offer Full Integration with Patient and ... Sechrist Industries , world leader in technology for ... and Chamber Ground-Check System which will provide verification of all ... ground requirements and is the first to be fully ...
... a Snapshot of Employer Health Benefits to Help Pharmaceutical ... NASHVILLE, Tenn., June 22 HealthLeaders-InterStudy, the leading provider ... version of Employer Vantage , a ... who the nation,s largest employers partner with for health ...
... ... ... Calm. Serene. These are the adjectives Hospice of Philadelphia considered when it ... own home is ideal, but is not always possible. Typically, patients requiring acute care ...
Cached Medicine News:Health News:Physician Dissatisfaction Leads to New Medical Conference 2Health News:Physician Dissatisfaction Leads to New Medical Conference 3Health News:Quest Diagnostics HemoCue Subsidiary to Add U.S. Hospital Laboratory Connectivity to Its HemoCue 201 DM Point-of-Care Systems 2Health News:Quest Diagnostics HemoCue Subsidiary to Add U.S. Hospital Laboratory Connectivity to Its HemoCue 201 DM Point-of-Care Systems 3Health News:The Nuts and Bolts of Reform Proposals 2Health News:The Nuts and Bolts of Reform Proposals 3Health News:Sechrist Industries Introduces Ground-Check System to Verify NFPA Ground Requirements in Hyperbaric Chambers 2Health News:HealthLeaders-InterStudy Unveils Enhanced Employer Vantage 2Health News:Unique Facility Designed for the Comfort of Hospice Patients and Their Families 2Health News:Unique Facility Designed for the Comfort of Hospice Patients and Their Families 3
... device allows for quick and ... ophthalmic surgical procedures. The "Quick ... through which a suture may ... during the loading procedure. The ...
Titanium. Small "H" shaped push-pull tip. Shaft angled 45 degrees, 9 mm from tip. Round knurled handle with dull finish. Overall length: 4.8 inches. Most popular size or model....
Left angled 5 mm blunt hook. Overall length: 9.9 inches....
This suture adjuster facilitates post operative suture adjustment of running sutures while decreasing the possibility of suture damage or breakage....
Medicine Products: